Abstract. In this study, we investigated the expression level of Ras-homologous (Rho) GTPases and the Rho guanine exchange factor (GEF) T-cell lymphoma invasion and metastasis 1 (Tiam1) in breast tumor specimens (n=106) by immunohistochemistry. Rho and Rho-GEF expression scores were compared to clinically established diagnostic and prognostic parameters. We found that RhoA and RhoB scores slightly increased with tumor grade, whereas the Rac1 score remained unaffected. The most significant effects were observed for the Rac1-specific GEF Tiam1. Tiam1 expression scores significantly decreased with the increase in tumor grade, tumor spreading and proliferation. Furthermore, Tiam1 expression was inversely related to the plasminogen activator inhibitor (PAI-1) and estrogen receptor (ER) expression but not the progesterone receptor (PR) and urokinase plasminogen activator (uPA). A low Tiam1 expression was associated with p53 positivity without being related to HER2/neu status. The data show that Tiam1 expression decreases with the progression of breast carcinomas and is inversely associated with several established breast tumor markers. Therefore, we suggest that Tiam1 counteracts the progression of breast carcinomas and is suitable as a novel breast tumor marker.
Introduction
Tumor progression and metastasis are characterized by a gain in proliferation, migration and invasive properties of tumor cells. Additionally, programmed cell death, which normally occurs as a consequence of loss of cell adhesion, needs to be by-passed. These alterations require fundamental changes in the cellular gene expression programme. Low molecular weight GTPases of the Rho family are central players in the regulation of many of these processes as demonstrated by numerous in vitro and in vivo studies (1) (2) (3) (4) (5) (6) . Western blot and RNA-based data show that Rho expression is related to the aggressiveness of several solid tumor types, including pancreas (7) and breast carcinomas (8) (9) (10) (11) . Surprisingly, an inverse association between Rho expression and the malignancy of brain tumors has been reported (12) . Furthermore, breast and colon cancer revealed an enhanced expression of the Rac splice variant Rac 1b (13) . Overexpression of Rho GTPases in tumors is suggested as a factor contributing to the putative anticancer effects of statins (14, 15) . Moreover, RhoB (16) and RhoE (17) were reported to have a tumor-suppressing function. The putative tumor suppressor property of RhoB may be related to its proapoptotic activity (18, 19) .
Apart from tumor-specific changes in the expression level of Rho proteins, it is assumed that the activity (i.e. GTPbinding) status of Rho proteins undergoes time-and spatialdependent fluctuations during the different steps involved in tumor progression and metastasis (2, 20) . As the activity status of Rho GTPases is regulated by Rho regulatory factors including guanine exchange factors (GEFs) such as Dbl, Tiam1 and Vav1, which are known to be oncogenic (21), changes in the expression level of these factors may also change with malignancy. For instance, the expression of Tiam1 (T-cell lymphoma invasion and metastasis 1) was found to be up-regulated in a subset of colorectal carcinomas (22) . Apart from Rho GEFs, the expression level of GTPaseactivating proteins (GAPs) or guanine dissociation-inhibiting proteins (Rho-GDI) may vary with malignancy, as a low Rho-GDI expression was recently observed in highly malignant grade III glioblastoma (23) . Thus, tumor-specific changes in Rho-regulated signaling may be reflected on the level of Rho protein expression and the expression level of Rho-regulatory factors.
Semiquantitative expression analysis of Rho GTPases and Rho-regulatory factors in malignant tissue by means of immunohistochemistry is lacking. However, this analysis is important as it supports the concept that they are of functional relevance for tumor progression, establishing them as clinically useful diagnostic and/or prognostic markers. Therefore, in the present study we analyzed the expression level of different types of Rho GTPases and GEFs in breast tumors, by employing immunohistochemistry. The obtained Rho and Rho GEF expression scores were related to clinically relevant breast tumor markers including tumor grade, spreading and type, and proliferation as well as the expression status of uPA, PAI-1, p53, Her2/neu and hormone receptors. The results obtained show that the expression score of the Rac1-specific GEF Tiam1 is significantly and inversely associated with several established breast tumor markers. This finding points to a particular relevance of Tiam1 for breast tumor progression and indicates that Tiam1 is useful as a novel breast tumor marker.
Materials and methods

Materials.
For morphological and immunohistochemical evaluation, routinely processed paraffin blocks of formalinfixed tumorigenic tissues from breast specimens were used. The histological grade of malignancy (G1/G2/G3), Ki-67 proliferation index (MIB-1), tumor spreading (T1-T4), tumor type (ductal, lobular and mixed), lymph node status, invasiveness, expression of urokinase plasminogen activator (uPA) and uPA-inhibitor type 1 (PAI-1), as well as p53, HER-2/neu oncogene and hormone receptor status (ER and PR) were established within routine pathological assessment. The n=105 paraffin-embedded breast tumor specimens (which underwent pathological consideration) were included in the study. RhoA-(no. sc-179, rabbit polyclonal), RhoB-(no. sc-180, rabbit polyclonal) as well as Tiam1-(no. sc-872, rabbit polyclonal) and Dbl-(no. sc-28582, rabbit polyclonal) specific antibodies were purchased from Santa Cruz (San Diego, USA). Rac1 (no. R56220, mouse monoclonal), Cdc42 (no. C70820, mouse monoclonal) and Vav1 (no. 07192) antibodies were purchased from Upstate (Hamburg, Germany).
Immunohistochemistry. Expression analysis of Rho and Rho regulatory factors in breast tissue was performed by conventional immunohistochemistry. Paraffin-embedded blocks of the formalin-fixed tumor samples were retrieved from the pathology archives of the Department of Obstetrics and Gynecology (University Hospital Mainz, Germany). Sections were immunostained for Rho GTPases (i.e. RhoA, RhoB, Rac1 and Cdc42) and Rho GEFs (Tiam1, Vav1 and Dbl) using the avidin biotin technique according to the standard protocol. Briefly, 6 μm sections were deparaffinized and rehydrated. Antigen retrieval by exposure of the section to hot steam [20 min in 1 mM EDTA buffer (pH 8.0)] was necessary only when Rac1-, Vav1-and Dbl-specific antibodies were used. Sections were quenched for endogenous peroxidase activity with 0.1% H 2 O 2 treatment (20 min) and then incubated with 10% normal goat serum (30 min) to block the non-specific binding of immunoglobulins to the tissue, followed by incubation with the corresponding antibodies (at a final dilution of 1:100-1:250; incubation overnight at room temperature). The ChemMate™Dako Envision detection kit (Dako Diagnostics, Hamburg, Germany) was used for visualization. Nuclei were lightly counterstained with hematoxylin. A microscopical calculation of the Rho/Rho-GEF scoring index in a given tumor sample was calculated by determining (i) the percentage of tumor cells that expressed the protein [score 0 (<10% of stained tumor cells) to 4 (>80% tumor cells stained)] and (ii) staining intensity [score 0 (no staining) to 3 (high staining)] resulting in an overall score ranging from 0 to 12. The data obtained are presented in a box-blot. Differences between two independent groups were analyzed for statistical significance using the Mann-Whitney U test, while differences among the groups were analyzed by the Kruskal-Wallis test. To check for correlation between the two factors, Spearman's test was applied. Two-sided P-values <0.05 were considered as statistically significant. Statistical analysis was performed using SigmaStat 3.5 software.
Results and Discussion
In the present study, we investigated the expression of Rho GTPases and GEFs in a breast tumor specimen by immunohistochemistry. We found that the expression level of the Rho GTPases RhoA, RhoB, Rac1 and Cdc42 as well as that of Rho GEFs Tiam1, Vav1 and Dbl is specifically enhanced in the malignant cells of breast as compared to the surrounding stroma cells (data not shown). In order to determine whether the immunohistochemically detectable expression of Rho and Rho GEFs is related to clinically established and relevant tumor markers of the breast, we investigated the expression of RhoA, RhoB, Rac1 and Tiam1 in n=105 breast tumor samples. The protein expression of Rho GTPases and Tiam1 was scored by combining the staining intensity and the percentage of tumor cells expressing Rho or Tiam1 protein. There was no statistically significant difference detectable between the expression scores of RhoA (Fig. 1A) , RhoB (Fig. 1B) and Rac1 (Fig. 1C) and the grade of malignancy. Only the percentage of RhoA-expressing cells significantly increased with the tumor grade (Table I) . A similar tendency, although statistically not significant, was also seen for RhoB and Rac1 (Table I) . A pairwise statistical analysis revealed a significant increase in RhoB expression from G1 to G2 grade tumors. G1 to G2 progression tends to result in an increase in the RhoA score (Table II) . Since Rac1 expression did not change with histological grading (Fig. 1C , Tables I and II) , the effects observed for RhoA and RhoB are considered as specific. Notably, the Tiam1 expression score significantly declined with the grade of malignancy (Fig. 1D ), in particular with the progression from G2 to G3 grade tumors (Table II) . As Tiam1 is a Rac1-specific guanine nucleotide exchange factor (24, 25) , the outcome of a reduced expression of Tiam1 can be assumed to be a decline in Rac1 activity. Consequently, a reduction in Rac1 activity may collaborate with the ongoing malignancy of breast tumors. Interestingly, RhoA and Rac1 have been reported to exert opposing biological effects (9, 25, 26) . With these reports in mind, we speculate that the reduced Tiam1 expression, and concomitant decrease in Rac1 activity, eventually promotes RhoA-regulated functions which are required for the progression of breast tumors. RhoC has also been suggested as a biomarker for aggressive breast carcinomas because a high RhoC expression was found to be predictive of poor survival of breast cancer patients (11) . Thus, RhoA and RhoC can functionally compensate for each other (9) .
The presence of lymph node metastases was neither significantly associated with the expression of Rho GTPases nor with Tiam1 (data not shown). However, a high proliferation index (MIB-1) was significantly related to a reduction in the Tiam1 score ( Fig. 2A ). An increase in tumor spread (Tclassification) was accompanied by a decrease of the Tiam1 expression score (Fig. 2B) . Interestingly, lobular breast tumors revealed a significantly higher Tiam1 expression than ductal or mixed-type tumors (Fig. 2C) . A significant association of Tiam1 expression was also observed with respect to plasminogen activator inhibitor type 1 (Fig. 2D) , with a high PAI-1 expression (>13 ng/ml protein) being related to a low Tiam1 score. An association of Tiam1 score with the expression level of urokinase plasminogen activator (uPA) was not observed (Table III) . No statistically significant correlations were detected between the expression scores of Rho GTPases and MIB-1, tumor size, tumor type, uPA or PAI-1 (Table III) .
We then investigated whether Rho and Tiam1 expression are associated with the p53, Her2/neu or hormone receptor status of breast tumors. We found p53 positivity to be significantly related to a high RhoA and a low Tiam1 score (Fig. 3A and B) . RhoB and Rac1 expression were not ONCOLOGY REPORTS 21: 217-222, 2009 Table I. Rho and Tiam1 expression is related to the grade of malignancy (G1/G2/G3) of breast tumors. - Table II . Rho and Tiam1 expression scores in breast tumors of different grading. .052 Table III . Summary of the associations observed between Rho and Tiam1 expression scores and clinically established diagnostic and prognostic parameters of breast tumors. - significantly related to p53 status (Table III) . It should be mentioned that the monoclonal p53 antibody used (Cat#OP43, Oncogene Research Products) detects wild-type and mutated p53. However, as the half-life of wild-type p53 is very short, immunohistochemical positivity reflects a mutated p53 protein.
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Regarding Her2/neu oncogene status, a clear tendency was detected for RhoA (p=0.052), whereas the expression levels of the other Rho GTPases and Tiam1 were not related to the expression of this oncogene (Table III) . Rho and Tiam1 scores failed to correlate with hormone receptor scores, although RhoB and Tiam1 scores tend to correlate with the ER score (p=0.062 and p=0.069; Table III) . By sub-grouping the breast tumors into tumors characterized by either a low (≤1) or high (>2) ER (or PR) score, we found that a low ER expression is associated with a low Tiam1 expression (Fig. 3C and Table III) . Results of the immunohistochemical studies are summarized in Table III . It illustrates the key finding of this study, which is that the statistically most significant effects were observed for Tiam1, which is a Rac-specific GEF (25) . The expression level of Tiam1 was inversely related to the grade of malignancy, tumor spreading, proliferation and PAI-1 expression as well as p53 status and is associated with a low ER expression status. Our findings are indicative of a particular relevance of Tiam1 in the progression of breast cancer. It is believed that the biological activity of Rho GTPases undergo time-and spatial-dependent fluctuations during epithelialmesenchymal transition (EMT) (20) . The data obtained in this study indicate that apart from the expression level of Rho GTPases, it is in particular the expression level of the Rac1-specific GEF Tiam1 that appears to contribute to a finely tuned regulation of Rho activities in the course of EMT. It is known that the biological effect of Tiam1 is cell type-specific and that Tiam1 can promote and inhibit epithelial cell migration (27, 28) . Regarding breast tumors, the observed decrease in Tiam1 expression collaborating with an increase in malignancy is taken as an indication that Tiam1 decelerates migration, presumably by promoting E-cadherin-mediated cell-cell contacts (28) .
In summary, based on the data we suggest that the downregulation of Tiam1 contributes to the progression of breast tumors. Therefore, Tiam1 is suitable as a novel breast tumor marker. Recently, the prognostic relevance of the Tiam1 expression was reported for prostate carcinomas (29) . Since Tiam1 is required for Rac1-triggered activation of stress kinases (30), which are key players in the regulation of anticancer drug-induced apoptosis (31, 32) , the observed changes in Tiam1 expression may impact on the therapeutic response of breast tumor cells to anticancer drugs. This important aspect will be the subject of forthcoming studies.
